IL103956A - Apolipoprotein dimers and pharmaceuticals containing them - Google Patents
Apolipoprotein dimers and pharmaceuticals containing themInfo
- Publication number
- IL103956A IL103956A IL10395692A IL10395692A IL103956A IL 103956 A IL103956 A IL 103956A IL 10395692 A IL10395692 A IL 10395692A IL 10395692 A IL10395692 A IL 10395692A IL 103956 A IL103956 A IL 103956A
- Authority
- IL
- Israel
- Prior art keywords
- dimer
- apo
- medicament
- apolipoprotein
- milano
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Ink Jet (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9103701A SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Apolipoprotein |
Publications (2)
Publication Number | Publication Date |
---|---|
IL103956A0 IL103956A0 (en) | 1993-05-13 |
IL103956A true IL103956A (en) | 1998-09-24 |
Family
ID=20384608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10395692A IL103956A (en) | 1991-12-13 | 1992-12-03 | Apolipoprotein dimers and pharmaceuticals containing them |
Country Status (28)
Country | Link |
---|---|
US (2) | US5876968A (fi) |
EP (1) | EP0571602B1 (fi) |
JP (1) | JPH07502892A (fi) |
AT (1) | ATE242269T1 (fi) |
AU (2) | AU3175593A (fi) |
BG (1) | BG61451B1 (fi) |
BR (1) | BR9205640A (fi) |
CA (1) | CA2103996C (fi) |
CZ (1) | CZ289879B6 (fi) |
DE (1) | DE69233092T2 (fi) |
DK (1) | DK0571602T3 (fi) |
EE (1) | EE03058B1 (fi) |
ES (1) | ES2199939T3 (fi) |
FI (1) | FI115771B (fi) |
HU (2) | HU217203B (fi) |
IL (1) | IL103956A (fi) |
MX (1) | MX9207224A (fi) |
NO (1) | NO315076B1 (fi) |
NZ (2) | NZ246223A (fi) |
PL (3) | PL172168B1 (fi) |
PT (1) | PT571602E (fi) |
RO (1) | RO115636B1 (fi) |
RU (1) | RU2134696C1 (fi) |
SE (1) | SE9103701D0 (fi) |
SG (1) | SG47453A1 (fi) |
SK (1) | SK86893A3 (fi) |
WO (1) | WO1993012143A1 (fi) |
ZA (1) | ZA928989B (fi) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9103701D0 (sv) * | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
SE9203753D0 (sv) * | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
SE9500778D0 (sv) * | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
FR2734568B1 (fr) * | 1995-05-22 | 1997-06-20 | Rhone Poulenc Rorer Sa | Nouveaux variants de l'apolipoproteine |
US6258596B1 (en) | 1995-05-22 | 2001-07-10 | Aventis Pharmaceuticals Products Inc. | Variants of apolipoprotein A-I |
SE9603068D0 (sv) | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
SE9603304D0 (sv) | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a compound |
SE9603303D0 (sv) | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a protein |
US6306433B1 (en) | 1997-08-12 | 2001-10-23 | Pharmacia Ab | Method of preparing pharmaceutical compositions |
US20020064820A1 (en) * | 2000-03-13 | 2002-05-30 | Jean-Michel Dayer | Apo-A-I regulation of T-cell signaling |
DE60117781T2 (de) | 2000-04-21 | 2006-11-23 | Amgen Inc., Thousand Oaks | Peptidderivate des apolipoproteins-a1/aii |
BRPI0003386B8 (pt) * | 2000-08-08 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas |
US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
CN1268641C (zh) | 2000-11-10 | 2006-08-09 | 普罗蒂奥制药公司 | 载脂蛋白类似物 |
US7217785B2 (en) * | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
IL161110A0 (en) * | 2001-09-28 | 2004-08-31 | Esperion Therapeutics Inc | Prevention and treatment of restenosis by local admistration of drug |
US20030229062A1 (en) * | 2001-12-07 | 2003-12-11 | The Regents Of The University Of California | Treatments for age-related macular degeneration (AMD) |
CA2468989A1 (en) * | 2001-12-07 | 2003-06-19 | Daniel M. Schwartz | Treatment for age-related macular degeneration |
US7470659B2 (en) * | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
US7223726B2 (en) * | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
US20100204103A1 (en) * | 2002-05-08 | 2010-08-12 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
US20040067873A1 (en) | 2002-05-17 | 2004-04-08 | Dasseux Jean-Louis H. | Method of treating dyslipidemic disorders |
WO2003097696A1 (en) * | 2002-05-17 | 2003-11-27 | Esperion Therapeutics, Inc. | Methods and copositions for the treatment of ischemic reperfusion |
DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
PE20050438A1 (es) * | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
WO2005051413A2 (en) * | 2003-11-26 | 2005-06-09 | Novartis Ag | Disease associated genes |
WO2005058938A2 (en) * | 2003-12-15 | 2005-06-30 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
JP2007531537A (ja) * | 2004-04-06 | 2007-11-08 | セダーズ−シナイ メディカル センター | アポリポタンパク質a−iおよびアポリポタンパク質a−imilanoをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置 |
KR100560102B1 (ko) * | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 a-ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
WO2012047930A2 (en) * | 2010-10-04 | 2012-04-12 | The Regents Of The University Of California | Compositions and methods for treatment of gynecologic cancers |
US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
EP1890715A4 (en) | 2005-04-29 | 2009-10-28 | Univ California | PEPTIDES AND PEPTIDE MIMETICS FOR TREATMENT BY INFLAMMATORY REACTION OF CHARACTERIZED PATHOLOGIES |
WO2007000924A1 (ja) * | 2005-06-28 | 2007-01-04 | Osaka University | プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法 |
KR100719389B1 (ko) | 2005-10-18 | 2007-05-17 | 주식회사 녹십자 | 인간혈장으로부터 아포리포단백질 a-i을 분리 정제하는방법 |
US20070254832A1 (en) * | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
WO2008021088A2 (en) | 2006-08-08 | 2008-02-21 | The Regents Of The University Of Californina | Salicylanilides enhance oral delivery of therapeutic peptides |
WO2008017906A1 (en) * | 2006-08-10 | 2008-02-14 | Plantechno S.R.L. | In-plant production of dimeric and/or oligomeric (comprising three or more units) forms of human apo a-1 protein muteins |
US8541236B2 (en) * | 2006-12-08 | 2013-09-24 | University Of Washington | Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls |
EP2195340A4 (en) | 2007-08-28 | 2011-05-11 | Uab Research Foundation | SYNTHETIC APOLIPOPROTEIN E-IMITATING POLYPEPTIDES AND METHOD OF USE |
CA2704729C (en) | 2007-08-28 | 2020-06-23 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
EP2207799A2 (en) * | 2007-10-19 | 2010-07-21 | Pronota NV | Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics |
EA201070517A1 (ru) | 2007-10-23 | 2010-12-30 | Дзе Кливленд Клиник Фаундейшн | Устойчивый к окислителям аполипопротеин а-1 и пептиды-миметики |
US8241861B1 (en) | 2008-07-08 | 2012-08-14 | Insilicos, Llc | Methods and compositions for diagnosis or prognosis of cardiovascular disease |
EP3808177A1 (en) | 2008-11-10 | 2021-04-21 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
CA3036963A1 (en) | 2009-01-29 | 2010-08-05 | Arbutus Biopharma Corporation | Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid |
US20100267806A1 (en) | 2009-03-12 | 2010-10-21 | David Bumcrot | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
EP2416760A4 (en) | 2009-05-05 | 2014-01-22 | Tekmira Pharmaceuticals Corp | LIPID COMPOSITIONS |
PL3431076T3 (pl) | 2009-06-10 | 2022-01-31 | Arbutus Biopharma Corporation | Ulepszona formulacja lipidowa |
WO2011020023A2 (en) | 2009-08-14 | 2011-02-17 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
US10525152B2 (en) | 2009-10-09 | 2020-01-07 | Signablok, Inc. | Methods and compositions for targeted imaging |
US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
CA2783372C (en) | 2009-12-07 | 2019-07-16 | Muthiah Manoharan | Compositions for nucleic acid delivery |
JP5749733B2 (ja) * | 2009-12-14 | 2015-07-15 | シル プロテインズ ゲーエムベーハーScil Proteins GmbH | フィブロネクチンのエキストラドメインbに対する特異的結合活性を有する修飾ユビキチンタンパク質 |
AU2010330814B2 (en) | 2009-12-18 | 2017-01-12 | Acuitas Therapeutics Inc. | Methods and compositions for delivery of nucleic acids |
US20130156845A1 (en) | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
WO2011143362A1 (en) * | 2010-05-11 | 2011-11-17 | Esperion Therapeutics, Inc. | Dimeric oxidation-resistant apolipoprotein a1 variants |
KR20190039347A (ko) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | 활성제의 전달을 위한 생분해성 지질 |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
US20130142760A1 (en) | 2010-08-18 | 2013-06-06 | Cedars-Sinai Medical Center | Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer |
US9339513B2 (en) | 2010-11-09 | 2016-05-17 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes |
EP3202760B1 (en) | 2011-01-11 | 2019-08-21 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
SI2767546T1 (sl) | 2011-02-07 | 2019-03-29 | Cerenis Therapeutics Holding Sa | Lipoproteinski kompleksi in izdelava ter uporaba le-teh |
AU2012268970B2 (en) | 2011-06-15 | 2016-01-28 | Navigo Proteins Gmbh | Dimeric binding proteins based on modified ubiquitins |
KR20140054115A (ko) | 2011-08-25 | 2014-05-08 | 에프. 호프만-라 로슈 아게 | 단축 테트라넥틴-아포지단백질 a-i 융합 단백질, 그를 함유하는 지질 입자 및 그의 용도 |
CA2849476A1 (en) | 2011-09-27 | 2013-04-04 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
US9610324B2 (en) | 2012-07-11 | 2017-04-04 | Esperion Therapeutics, Inc. | Apolipoprotein mixtures |
EP2853259A1 (en) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
KR20170003611A (ko) | 2014-05-02 | 2017-01-09 | 세레니스 쎄라퓨틱스 홀딩 에스에이 | Hdl 요법 마커 |
US10653747B2 (en) | 2014-07-31 | 2020-05-19 | Uab Research Foundation | ApoE mimetic peptides and higher potency to clear plasma cholesterol |
CA2975362A1 (en) | 2015-02-06 | 2016-08-11 | Navigo Proteins Gmbh | Egfr binding proteins comprising ubiquitin muteins |
CN107922483B (zh) | 2015-07-16 | 2021-07-30 | 纳维格蛋白质有限公司 | 新型免疫球蛋白结合蛋白及其在亲和纯化中的用途 |
JP2018520675A (ja) | 2015-07-20 | 2018-08-02 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH | ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法 |
CN109310780A (zh) | 2016-05-04 | 2019-02-05 | 纳维格蛋白质有限公司 | 包含肽接头的用于化学部分位点-特异性偶联的靶向化合物 |
EP3497118B1 (en) | 2016-08-11 | 2022-09-14 | Repligen Corporation | Alkaline stable fc binding proteins for affinity chromatography |
US20190048049A1 (en) | 2017-08-10 | 2019-02-14 | Cerenis Therapeutics Holding Sa | Cargomers |
WO2019030575A1 (en) | 2017-08-10 | 2019-02-14 | Cerenis Therapeutics Holding | APOMÈRES |
EP3706804B1 (en) | 2017-11-07 | 2022-02-23 | Navigo Proteins GmbH | Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer |
WO2021209823A1 (en) | 2020-04-16 | 2021-10-21 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein- based complexes |
CN116322646A (zh) | 2020-10-01 | 2023-06-23 | 阿比奥尼克斯制药公司 | 用于治疗眼病的包含基于脂质结合蛋白的复合物的组合物 |
EP4322746A1 (en) | 2021-04-15 | 2024-02-21 | Abionyx Pharma SA | Use of lipid binding protein-based complexes in organ preservation solutions |
WO2023194797A1 (en) | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
WO2023194798A1 (en) | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
WO2023237927A2 (en) | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes |
WO2023237935A2 (en) | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein-based complexes |
WO2024150064A1 (en) | 2023-01-13 | 2024-07-18 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8625435D0 (en) * | 1986-10-23 | 1986-11-26 | Erba Farmitalia | Human apolipoprotein ai |
IT1229996B (it) * | 1989-04-20 | 1991-09-20 | Cesare Sirtori | Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine. |
SE9103701D0 (sv) * | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
-
1991
- 1991-12-13 SE SE9103701A patent/SE9103701D0/xx unknown
-
1992
- 1992-11-20 ZA ZA928989A patent/ZA928989B/xx unknown
- 1992-12-03 IL IL10395692A patent/IL103956A/en not_active IP Right Cessation
- 1992-12-11 PL PL92314896A patent/PL172168B1/pl unknown
- 1992-12-11 US US08/104,063 patent/US5876968A/en not_active Expired - Lifetime
- 1992-12-11 RO RO93-01116A patent/RO115636B1/ro unknown
- 1992-12-11 NZ NZ246223A patent/NZ246223A/en unknown
- 1992-12-11 PL PL92314894A patent/PL172544B1/pl not_active IP Right Cessation
- 1992-12-11 CA CA002103996A patent/CA2103996C/en not_active Expired - Fee Related
- 1992-12-11 PT PT93900484T patent/PT571602E/pt unknown
- 1992-12-11 PL PL92300262A patent/PL171907B1/pl not_active IP Right Cessation
- 1992-12-11 MX MX9207224A patent/MX9207224A/es unknown
- 1992-12-11 DK DK93900484T patent/DK0571602T3/da active
- 1992-12-11 SG SG1996001800A patent/SG47453A1/en unknown
- 1992-12-11 JP JP5510842A patent/JPH07502892A/ja active Pending
- 1992-12-11 CZ CZ19931589A patent/CZ289879B6/cs not_active IP Right Cessation
- 1992-12-11 NZ NZ280516A patent/NZ280516A/en unknown
- 1992-12-11 RU RU93054168A patent/RU2134696C1/ru not_active IP Right Cessation
- 1992-12-11 ES ES93900484T patent/ES2199939T3/es not_active Expired - Lifetime
- 1992-12-11 HU HU9302344A patent/HU217203B/hu not_active IP Right Cessation
- 1992-12-11 WO PCT/SE1992/000858 patent/WO1993012143A1/en active IP Right Grant
- 1992-12-11 BR BR9205640A patent/BR9205640A/pt not_active Application Discontinuation
- 1992-12-11 AU AU31755/93A patent/AU3175593A/en not_active Abandoned
- 1992-12-11 AT AT93900484T patent/ATE242269T1/de not_active IP Right Cessation
- 1992-12-11 EP EP93900484A patent/EP0571602B1/en not_active Expired - Lifetime
- 1992-12-11 DE DE69233092T patent/DE69233092T2/de not_active Expired - Lifetime
- 1992-12-11 SK SK868-93A patent/SK86893A3/sk unknown
-
1993
- 1993-08-11 BG BG98036A patent/BG61451B1/bg unknown
- 1993-08-12 NO NO19932866A patent/NO315076B1/no not_active IP Right Cessation
- 1993-08-12 FI FI933557A patent/FI115771B/fi not_active IP Right Cessation
-
1994
- 1994-11-16 EE EE9400375A patent/EE03058B1/xx unknown
-
1995
- 1995-06-30 HU HU95P/P00630P patent/HU211667A9/hu unknown
-
1996
- 1996-07-12 AU AU59473/96A patent/AU703283B2/en not_active Ceased
-
1999
- 1999-03-01 US US09/259,434 patent/US6617134B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL103956A (en) | Apolipoprotein dimers and pharmaceuticals containing them | |
Gaubatz et al. | Isolation and characterization of the two major apoproteins in human lipoprotein [a]. | |
Xu et al. | Human growth hormone expressed in tobacco cells as an arabinogalactan-protein fusion glycoprotein has a prolonged serum life | |
Vogel et al. | Human apolipoprotein E expression in Escherichia coli: structural and functional identity of the bacterially produced protein with plasma apolipoprotein E. | |
Boyles et al. | Identification, characterization, and tissue distribution of apolipoprotein D in the rat. | |
Okamura et al. | A porcine homolog of the major secretory protein of human epididymis, HE1, specifically binds cholesterol | |
Calabresi et al. | Molecular characterization of native and recombinant apolipoprotein A-IMilano dimer. The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein AI. | |
FI94876C (fi) | Menetelmä aprotiniinin valmistamiseksi yhdistelmä-DNA-tekniikalla ja menetelmään soveltuva DNA, ilmentämisplasmidi ja isäntäsolu | |
JP3082941B2 (ja) | ヒト・アポリポ蛋白質aiおよびai―ミラノの酵母での発現 | |
EP0267703B1 (en) | Human apolipoprotein ai and variant form of the same expressed in escherichia coli | |
US7223726B2 (en) | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same | |
Butkowski et al. | Characterization of type IV collagen NC1 monomers and Goodpasture antigen in human renal basement membranes | |
KR20130047749A (ko) | 테트라넥틴-아포지단백질 a-i 지질 입자의 제조 방법, 지질 입자 및 이의 용도 | |
JP2002191385A (ja) | 三つ葉状のペプチド2量体 | |
Nikawa et al. | Studies on the reactive site of the cystatin superfamily using recombinant cystatin A mutants: Evidence that the QVVAG region is not essential for cysteine proteinase inhibitory activities | |
EP0934337B1 (en) | A process for purifying apolipoprotein a or apolipoprotein e from human plasma | |
Pillot et al. | Single-Step Purification of Two Functional Human Apolipoprotein E Variants Hyperexpressed inEscherichia coli | |
KR20130117760A (ko) | 테트라넥틴-아포지단백질 a-i 입자의 제조 방법, 이에 의해 제조된 지질 입자 및 이의 용도 | |
KR20140054115A (ko) | 단축 테트라넥틴-아포지단백질 a-i 융합 단백질, 그를 함유하는 지질 입자 및 그의 용도 | |
JP2012509670A (ja) | 血液凝固促進剤としてのヘビ第五因子及び使用方法 | |
Leroy et al. | Expression, location and cross-reactivity of two antigenic sites on the amino terminal region of rabbit and human apolipoprotein AI |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
HP | Change in proprietorship | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |